On August 22, 2022, the National Pharmaceutical Innovation Development and R&D Cooperation Forum and the 2022 Nanjing Station of the Laowen Trade Expo of New Technology Nanjing was grandly opened at Shangri-La Hotel, Nanjing, and FarmaSino Co., Ltd. was invited to participate in the exhibition, comprehensively displaying the six core businesses, consolidating existing cooperative relationships, exploring potential customers, and laying the foundation for market development. The conference was hosted by BIO-WELCOME and Futureway Pharmaceutical Technology (Beijing) Co., Ltd., bringing together a number of entrepreneurs and executives from China, and more than 50 pharmaceutical and health production and sales enterprises participated in the exhibition, and was known as the "highland of industry resources and intelligence concentration". The conference builds a platform for the industry to promote information flow, help the rapid development of the industry, and at the same time provide enterprises with more industry communication and business development opportunities, helping enterprises quickly find: CRO new drugs under development, 505b2 and other difficult technologies; Resources such as scarce products for popular indication channels.

FarmaSino 's 2022 year-end summary conference. On January 8, FarmaSino Co., Ltd. held the 2022 annual work summary and advanced commendation conference in the conference room of the headquarters building. At the beginning of the meeting, the leaders of various departments reported the business results in 2022, comprehensively analyzed the gains and losses in the work, and planned and looked forward to the work in 2023. Next, the company recognized the advanced individuals and teams that emerged this year. The last session of the conference was delivered by Yan Libo, Chairman of FarmaSino, who introduced to all employees the company's brilliant performance in 2022, and the company's sales exceeded 200 million US dollars for the first time since its establishment, an increase of more than 30% year-on-year, achieving a milestone leap in business performance.

Congratulations! Farmasino 's strategic investment shareholder Novezan was listed on the Science and Technology Innovation Board! The total market capitalization exceeds 37 billion! On the morning of November 15, 2021, Nanjing Novezan Biotechnology Co., Ltd., a strategic investment shareholder of Farmasino, was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Stock abbreviation: Novezan Stock code: 688105. Founded in 2012, Nanjing Novezan Biotechnology Co., Ltd. is a biotechnology enterprise focusing on enzymes, antigens, antibodies and other functional proteins and polymer organic materials for technology research and development and product development, relying on the key common technology platform independently established, has entered the field of biological reagents, in vitro diagnostic business, and is conducting the research and development of antibody drugs, is one of the few domestic R & D innovative enterprises with independent and controllable upstream technology development capabilities and terminal product production capacity.